The U.S. Senate took action to repeal the Affordable Care Act sending the markets tumbling to a sharply lower open with the Dow plummeting 154 points to 19,800. Nasdaq plunged 56 points to 5,507.
On the upside
The American Journal of Sports Medicine published an article analyzing magnetic resonance imaging data through 60 months follow up from Phase 1 and Phase 2 clinical trials of Histogenics' (Nasdaq: HSGX) NeoCart for the repair of articular cartilage knee injuries.
Applied Optoelectronics (Nasdaq: AAOI) reported preliminary fourth quarter earnings and revenue that topped previous guidance.
Cellect Biotechnology (Nasdaq: APOP) received a notice of allowance from the U.S. Patent & Trademark Office for a patent to protect the company's technology to treat multiple medical conditions.
On the downside
Investors locked in profits on Biocept (Nasdaq: BIOC).
Profit taking weighed down shares of MYOS RENS Technology (Nasdaq: MYOS).
Vista Outdoor (NYSE: VSTO) warned that it would record a material, non-cash intangible asset impairment charge in the third quarter.
In the broad market, declining issues outpaced advancers by a margin of more than 5 to 2 on the NYSE and by nearly 7 to 2 on Nasdaq. The broader S&P 500 index dropped 16 points to 2,258. Bitcoin edged up to $784.
